Description
Prazinec (Praziquantel) 600 mg
Prazinec is a praziquantel product. Praziquantel is a broad-spectrum anthelmintic used against several parasitic worm infections, especially fluke and tapeworm infections. The supplied product name is used here only as an identification clue; the verified active ingredient is praziquantel.
Active Ingredient and Medicine Class
The active ingredient is praziquantel, an anthelmintic and trematodicide. Regulatory labeling identifies praziquantel tablets as oral medicine with 600 mg strength.
Established Medical Uses
Praziquantel is established for the treatment of certain parasitic worm infections, including schistosomiasis and other trematode and cestode infections. Official U.S. labeling specifically includes schistosomiasis due to Schistosoma mansoni, S. haematobium, S. japonicum, S. mekongi, and S. intercalatum, and also taeniasis due to Taenia solium and Taenia saginata.
How It Works
Praziquantel damages susceptible parasites by increasing membrane permeability to calcium, which leads to paralysis and disruption of the worm’s outer surface. This makes the parasites easier for the host immune system to clear. The exact mechanism is not fully understood, but this calcium-dependent effect is the accepted explanation in current scientific reviews.
Important Safety Information
Praziquantel is contraindicated in people with known hypersensitivity to praziquantel or product excipients, in patients with ocular cysticercosis, and with strong CYP3A inducers such as rifampin because effective drug levels may not be achieved. U.S. labeling also warns about possible cardiac arrhythmias and recommends caution in hepatic impairment, where exposure can be increased. Moderate CYP3A inducers may reduce effectiveness.
Possible Side Effects
Commonly reported adverse effects include headache, dizziness, abdominal pain, nausea, vomiting, fatigue, and fever. More serious reactions have included cardiac rhythm disturbances, hypersensitivity reactions, and worsening symptoms related to parasite death in some settings.
Scientific Evidence
Peer-reviewed reviews describe praziquantel as the mainstay treatment for schistosomiasis and an important option for several other trematode and cestode infections. Clinical literature supports good overall efficacy and tolerability, while also noting that response can vary by parasite species and disease burden.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or individual assessment by a qualified health professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed, Praziquantel tablets, prescribing information.
- Bayer, Biltricide (praziquantel) tablets, FDA label.
- Jong-Yil Chai et al., “Praziquantel treatment in trematode and cestode infections: an update,” Infection and Chemotherapy, 2014. PubMed.
